Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANRS-PREVENIR: PrEP with Truvada for HIV Prevention
NCT03113123Unknown
- Sponsor
- ANRS
- Start
- May 2017
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of emtricitabine + tenofovir disoproxil in human immunodeficiency virus infection (HIV), sponsored by ANRS. Primary endpoint: Reduction of new HIV diagnosis at 3 years. Status: unknown.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03113123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113123.